Epilepsy

Current Location

74 Epilepsy Trials Near You

Power is an online platform that helps thousands of Epilepsy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

105 Participants Needed

This study will be done in two phases. Using stakeholder input (community advisory board (CAB)), the study team will adapt the SMART program to incorporate education and self-management support for use of Rescue Medication (RM) to manage seizure occurrence among Persons With Epilepsy (PWE) who have repetitive seizures. Additional content/support materials, pending input stakeholder might include posters/hand-outs that present information on the use of RM in a way that is engaging and salient to PWE. It is expected that participants will be in Phase 1 for about 3 months and participate in the CAB 2 or 3 times via zoom for 60-90 minutes/meeting. The advisory board will provide input on needed refinement of an adapted version of SMART based on their individual experiences. It is anticipate the total time commitment to be no more than 6 hours over 3 months, spread out over 2-3 meetings with review of materials possible in between meetings. Phase 2: The investigators will use a 6-month prospective trial design to test engagement with and effects of SMART-RM among approximately 35 adult (≥ 18 years) PWE who have repetitive seizures.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

43 Participants Needed

The goal of this clinical trial is to learn if new educational program prior to epilepsy surgery can either decrease the risk of cognitive decline after surgery or be a help to those patients who experience a decline after undergoing epilepsy surgery. Participants will participate in 2 individual virtual sessions and 4 virtual group sessions over the course of 5-6 weeks prior to their epilepsy surgery. They will asked to fill out online surveys and questionnaires at various times throughout the study, up to 12 months after their surgery. To see if the educational program works, researchers will compare those participating in the educational program with those that are receiving the standard epilepsy care prior to surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

64 Participants Needed

This trial tests if online group sessions led by a brain health expert can help people with epilepsy improve their thinking and memory skills. Participants will join regular sessions for a few months and then practice on their own for several more months. The goal is to see if these mental exercises can enhance daily functioning and overall brain health.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

170 Participants Needed

The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in US
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

110 Participants Needed

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65

20 Participants Needed

A prospective controlled, randomized study to examine the effects of behavioral and wellness-based interventions on seizure frequency for adult patients with medication resistant epilepsy who are still experiencing 1 or more seizures per month.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1000 Participants Needed

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2+

412 Participants Needed

The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:4 - 12

24 Participants Needed

This trial tests if a mix of healthy activities and education can help people at risk of neurological disorders. Participants will do brain exercises, yoga, music therapy, and follow a healthy diet. The goal is to see if these activities can keep their brains healthier and delay or prevent neurological issues.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50+

200 Participants Needed

BHV-7000 for Epilepsy

Lexington, Kentucky
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

242 Participants Needed

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 65

156 Participants Needed

This trial tests a device that monitors muscle activity to detect seizures in veterans with arm-involved motor seizures. The device alerts users when it detects unusual muscle movements, helping to identify seizures.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+

5 Participants Needed

BHV-7000 for Epilepsy

Pittsburgh, Pennsylvania
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

390 Participants Needed

To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+

100 Participants Needed

The study is a multi-site study and will be conducted at up to 11 investigative sites in the United States. The study will investigate subcortical arousal circuits in visual perception using techniques with complementary strengths based on promising initial studies.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:13+

72 Participants Needed

The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group. * Patients that receive the Epilepsy Visit Planner will have improved quality of life scores. * The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study. Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

162 Participants Needed

Statistical Learning for Epilepsy

Pittsburgh, Pennsylvania
The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane. The temporal lobe has long been established as a region of interest in the speech perception and processing literature because it contains the auditory cortex. More recently, research has localized the supratemporal plane as an area that exhibits response specificity to acoustic properties of complex auditory signals like speech. The supratemporal plane, comprised of Heschl's gyrus, the planum polare, and the planum temporale, is capable of the rapid spectrotemporal analysis required to map acoustic information to linguistic representation. Neural activity in this area, however, is rarely studied directly because it is difficult to access with non-invasive measures like scalp electroencephalography (EEG). Capitalizing on the unique opportunity to access these areas via routine clinical stereoelectroencephalography (sEEG) in a patient population, this study seeks to understand how cortical responses reflect the diagnosticity of two acoustic-phonetic dimensions of interest and how responses rapidly and flexibly adapt to changes in listening demands. Examining how neural response to voice onset time (VOT) and fundamental frequency (F0) modulates as a function of perceptual weight carried in signaling phoneme categories, and identifying how changes in listening context shift perceptual weight, will provide invaluable data that indicates how speech processing flexibly adapts to short-term acoustic patterns.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:15 - 25

25 Participants Needed

This project will test the accuracy of a novel diffusion-weighted magnetic resonance imaging (DWMRI) approach using a deep convolutional neural network (DCNN) to predict an optimal resection margin for pediatric epilepsy surgery objectively. Its primary goal is to minimize surgical risk probability (i.e., functional deficit) and maximize surgical benefit probability (i.e., seizure freedom) by precisely localizing eloquent white matter pathways in children and adolescents with drug-resistant focal epilepsy. This new imaging approach, which will acquire a DWMRI scan before pediatric epilepsy surgery in about 10 minutes without contrast administration (and also without sedation even in young children), can be readily applied to improve preoperative benefit-risk evaluation for pediatric epilepsy surgery in the future. The investigators will also study how the advanced DWMRI-DCNN connectome approach can detect complex signs of brain neuronal reorganization that help improve neurological and cognitive outcomes following pediatric epilepsy surgery. This new imaging approach could benefit targeted interventions in the future to minimize neurocognitive deficits in affected children. All enrolled subjects will undergo advanced brain MRI and neurocognitive evaluation to achieve these goals. The findings of this project will not guide any clinical decision-making or clinical intervention until the studied approach is thoroughly validated.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:3 - 19

60 Participants Needed

This trial tests if injecting special brain cells into the brain can help patients with hard-to-treat epilepsy. The new cells release a calming chemical to reduce seizures. Patients will also take medicines to prevent their bodies from rejecting the new cells.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

58 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

STK-001 for Dravet Syndrome

Ann Arbor, Michigan
This trial is testing the safety of STK-001, a new treatment for Dravet syndrome. It aims to help patients by increasing a brain protein that is usually low in this condition. The study focuses on patients who have already tried this treatment in earlier studies.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:30+

60 Participants Needed

This trial is testing Perampanel, a drug that blocks overactive brain signals, to help patients with severe seizures that don't respond to other treatments. The study aims to see if this drug can effectively and safely control these difficult-to-treat seizures.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

25 Participants Needed

VNS for Epilepsy

Louisville, Kentucky
Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for epilepsy in the 1990s and is commonly performed as an outpatient surgery. The mechanism of action is not well understood; however it is increasingly recognized that electrical stimulation of the vagus nerve may impact other organ systems in the body including the immune and gastrointestinal systems. Concrete characterization of the peripheral effects of VNS in human gut microbiome and immune systems will: (1) elucidate peripheral mechanism of action of chronic VNS therapy, (2) identify peripheral preoperative biomarker of VNS efficacy, and (3) create a foundation for research investigating new GM and IM-related disease indications for VNS. The primary objective of this study is to characterize the pre- and post-operative oral and gut microbiome of patients implanted with vagal nerve stimulator (VNS) for epilepsy. Secondary objectives of this study include: (1) to characterize the pre-operative and post-operative immune profile of patients undergoing VNS implantation for epilepsy, (2) to elucidate whether oral and/or gut microbiota changes are related to VNS efficacy for epilepsy and (3) identification of a biomarker predicting VNS efficacy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:0 - 60

30 Participants Needed

To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17

200 Participants Needed

This prospective double blind phase II study seeks to evaluate the safety and efficacy of BRC-003, a high CBD investigational product, in the treatment of refractory PTE (Post-Traumatic Epilepsy). The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B). This design aims to provide a thorough understanding of the investigational product's impact on seizure frequency, seizure severity, mood, anxiety, sleep, and quality of life.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

50 Participants Needed

Lacosamide for Neonatal Seizures

Charlottesville, Virginia
The purpose of the study is to evaluate the efficacy of lacosamide (LCM) versus an Active Comparator chosen based on standard of care (StOC) in severe and nonsevere seizure burden (defined as total minutes of electroencephalographic neonatal seizures (ENS) per hour) in neonates with seizures that are not adequately controlled with previous anti-epileptic drug (AED) treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:< 28

32 Participants Needed

NBI-921352 for Epilepsy

Chicago, Illinois
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
Stay on current meds

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 21

52 Participants Needed

Focused Ultrasound for Epilepsy

Charlottesville, Virginia
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

8 Participants Needed

NRTX-1001 for Temporal Lobe Epilepsy

Charlottesville, Virginia
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

10 Participants Needed

The aim of this pilot study is to understand hippocampal network function in mesial temporal lobe epilepsy (MTLE) and to test whether transcranial magnetic stimulation (TMS) targeting the network of the hippocampus can change hippocampal-dependent memory task performance and epileptic activity in people with (MTLE). Positive findings would implicate the hippocampal network as a source of these typical primary MTLE symptoms. Subjects with a primary diagnosis of MTLE will be enrolled in a non-randomized, non-blinded pilot experiment to test target engagement and preliminary efficacy of a novel neurostimulation approach targeting the hippocampal network. At baseline, subjects will undergo neurocognitive testing for hippocampal-dependent memory and functional magnetic resonance imagining (fMRI) neuroimaging assessment of brain structure and task-dependent activity. They will also receive scalp-electroencephalography (EEG) to measure interictal epileptiform discharge (IED) frequency at baseline, and will complete a seizure diary for one month. They will then receive high-frequency repetitive TMS targeting an area of parieto-occipital cortex defined based on fMRI connectivity with the hippocampus measured at baseline. The baseline assessments will then be repeated, using an alternate form of the memory test. The investigators will analyze changes from baseline in memory task performance, fMRI activity of the hippocampal network, IED frequency, and reported seizure frequency.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

34 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Epilepsy clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Epilepsy clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Epilepsy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Epilepsy is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Epilepsy medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Epilepsy clinical trials?

Most recently, we added Subcortical Arousal Study for Epilepsy, Zonisamide for Partial Seizures and Zorevunersen for Dravet Syndrome to the Power online platform.

What are the current treatments for epilepsy?

Treatment usually starts with daily anti-seizure medicines—over 20 are available—and about two-thirds of people become seizure-free after trying one or two of them. If seizures continue, specialists can offer individualized next steps such as surgery to remove the seizure focus, implantable stimulators that “pace” the nerves or brain (VNS, RNS, deep-brain stimulation), dietary therapy like the ketogenic or modified Atkins diet, or newer drugs including purified cannabidiol. The best plan depends on seizure type, age, other health issues and personal preferences, so care is built in partnership with an epilepsy team.

Are you born with epilepsy or does it develop?

Epilepsy can start two ways: you might be born with an underlying change in the brain — for example a genetic mutation or a problem that occurred during pregnancy or birth — or you can develop it later after things like a head injury, stroke, tumour or serious brain infection. Roughly one-third of cases are clearly “present from birth,” another third are due to later brain injuries or illnesses, and the rest have no obvious cause yet. In short, some people are born with the tendency, but anyone can develop epilepsy at any age if new damage or disease affects the brain’s electrical circuits.

What is the rule of 3 for seizures?

The ILAE’s “Rule of 3” says you can call someone seizure-free when they have gone at least three times as long as their single longest gap between seizures before the new treatment—and in any case at least 12 months—without another event. For example, if the longest break before treatment was 2 months, you need 6 months but because the rule also sets a 12-month minimum you would actually wait a full year; if the longest break was 8 months, you would need 24 months seizure-free. This personalised yard-stick helps doctors judge whether an intervention is truly working and avoids declaring success either too early (for people who naturally had long intervals) or too late (for those who seized frequently).

What is the most serious epilepsy?

The most immediately life-threatening situation is status epilepticus—any seizure that lasts five minutes or more or comes back before the person regains awareness; if this happens, give any prescribed rescue medicine and call emergency services because every extra minute increases the risk of brain injury or death. Over the long term, rare drug-resistant childhood syndromes such as Dravet or Lennox-Gastaut are often labeled the “most serious” because they cause daily seizures, developmental problems, and a higher risk of sudden death, so they require care at a specialized epilepsy center and a written emergency plan.

How likely is epilepsy to go away?

About two-thirds of children and roughly 60 % of adults who are just starting treatment become seizure-free long-term with medication alone. If seizures continue after trying two suitable drugs, the chance they stop on their own is small (under 5 % per year), but surgery or other specialised treatments can lift the seizure-free rate to about 50-70 % in people who are good candidates. Your exact odds depend on the epilepsy type, brain scans and early response to medicine, so work with your neurologist before deciding whether to stay on, stop, or escalate treatment.

What foods prevent seizures?

No single food can guarantee seizure prevention. What has solid evidence is a medically supervised, high-fat/very-low-carb diet (classic ketogenic or its easier cousins, the modified Atkins and low-glycaemic-index plans), which can reduce seizure frequency in about half of patients and make some seizure-free. If you’re not on one of these programs, aim for steady blood-sugar meals—plenty of non-starchy vegetables, healthy fats (olive oil, avocado, nuts, fatty fish), regular protein, and minimal added sugar—and talk with your neurologist or a dietitian before making major changes.

What do people with epilepsy struggle with?

People with epilepsy usually face two overlapping hurdles: the seizures themselves—figuring out triggers, preventing injuries, and coping with restrictions on driving, work, or sports—and the wider “after-shocks,” such as memory lapses, mood problems, medication side-effects, stigma, and added financial or school stress. Pinpointing which of these areas is causing the most strain and partnering with a neurologist on medication adherence, mental-health care, safety planning, and community support can greatly reduce risk and help regain independence.

What is the difference between a seizure and an epilepsy?

Think of a seizure as a one-time electrical “short-circuit” in the brain that can be set off by things like fever, low blood sugar, or head injury; once the trigger is gone, the risk may disappear. Epilepsy is the medical disorder in which the brain itself has an ongoing tendency to seize—diagnosed when someone has at least two unprovoked seizures (or one unprovoked seizure with a high chance of another), so the focus shifts from treating a single event to managing a long-term condition.

What is the best epilepsy hospital in the world?

There is no single “best” epilepsy hospital; what matters is choosing a center that holds the top accreditation for complex epilepsy care (e.g., NAEC Level 4 in the U.S. or an equivalent comprehensive program elsewhere), performs a high number of epilepsy surgeries with good outcomes, and has a multidisciplinary team and active research program. Examples that fit these benchmarks include Mayo Clinic and Cleveland Clinic (USA), King’s College Hospital/UCL in London (UK), University of Bonn (Germany), Pitié-Salpêtrière (France), Toronto Western Hospital (Canada), and Tokyo University Hospital (Japan). Ask your neurologist or local epilepsy foundation which accredited comprehensive center is closest and best suited to your insurance, travel limits, and whether you need adult or pediatric care.

What is the best exercise for a seizure patient?

There’s no single “best” exercise for epilepsy—the goal is to choose any activity you enjoy (brisk walking, cycling, swimming with a buddy, light weights, yoga) and do it regularly enough to meet general health targets of ~150 minutes of moderate movement plus two strength sessions weekly. Apply a safety layer: take medications on schedule, avoid personal triggers, wear a medical ID, and have supervision for water or height-related sports; studies and international guidelines show this approach improves fitness, mood, and often reduces seizures without added risk. Always confirm details with your neurologist so the plan fits your seizure pattern and other health factors.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security